SC Filed 2023-12-18 Event — SEC 0001193125-23-297638 →

SR ONE CAPITAL MANAGEMENT, LLC → Arcellx, Inc. ACLX

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

8 13D/G filings on this issuer

7 other filings besides this one

Filer Track Record

8 filings by this filer

7 other filings in the data moat

Short Interest · settle 2026-04-15

DTC 2.52

1,800,274 shares short · -20.7% vs prior

Other 13D/G Filings on Arcellx, Inc.

Filed	Form	Filer	Stake	Shares
2026-04-30	SCHEDULE 13D/A	New Enterprise Associates 15, L.P.	—	0	view →
2026-04-28	SCHEDULE 13D/A	GILEAD SCIENCES, INC.	—	100	view →
2026-04-28	SCHEDULE 13D/A	Elghandour Rami	—	0	view →
2025-02-27	SCHEDULE	Elghandour Rami	6.90%	3,997,132	view →
2023-06-02	SC	SR ONE CAPITAL MANAGEMENT, LLC	—	—	view →
2023-01-24	SC	New Enterprise Associates 15, L.P.	—	—	view →
2022-06-27	SC	SR ONE CAPITAL MANAGEMENT, LLC	—	—	view →

Other Filings by SR ONE CAPITAL MANAGEMENT, LLC

Filed	Form	Issuer	Stake	Shares
2026-10-05	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	9.30%	9,936,661	view →
2026-08-17	SCHEDULE 13D/A	Zenas BioPharma, Inc.	—	5,037,854	view →
2026-08-14	SCHEDULE 13D/A	Veradermics, Inc.	—	2,080,119	view →
2026-05-18	SCHEDULE 13D	Odyssey Therapeutics, Inc. ODTX	8.00%	3,794,883	view →
2025-10-01	SCHEDULE	KALA BIO, Inc. KALA	5.50%	411,000	view →
2023-06-02	SC	Arcellx, Inc. ACLX	—	—	view →
2022-06-27	SC	Arcellx, Inc. ACLX	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →